Pregabalin as a probable cause of central serous chorioretinopathy: Two case reports

Doğan, Yusuf Emre; Oktay, Kübra Neslihan Kurt; Özkurt, Yelda Buyru; Aktaş, İlknur

doi:10.5606/tftrd.2021.5433

Cited by 5 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pregabalin as an L‐type calcium channel antagonist can lead to vasodilation of choroidal vessels in BRB which can cause retinal oedema (Makani et al, 2011). Most recently, it was associated with the development of central serous chorioretinopathy (Doğan et al, 2021). Herein, we found that it could also be associated with an increased risk of DME in persons with diabetes.…”

Section: Discussionmentioning

confidence: 99%

Development of diabetic macular oedema shows associations with systemic medication – An epidemiological study

Loukovaara,

Korhonen,

Niskanen

et al. 2023

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeTo identify associations between systemic drugs and the incidence of diabetic macular oedema (DME). Of interest was to find beneficial and/or deleterious associations of used drugs.MethodsA historic cohort design based on administrative data. Study population consisted of 150 353 individuals with diabetes. Endpoint event was the development of DME (ICD‐10 H36.01), censoring events were death or study end December 2017. The follow‐up started between 1997 and 2010. The systemic medication consisted of 95 substances. We constructed a nested case–control study design comparing 2630 cases with DME to 13 144 age‐ and sex‐matched controls without DME. Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs) based on conditional logistic regression models.ResultsIncidence rate for DME was 1.80 per 1000 person‐years (95% CI 1.73–1.87). In all, we observed a lower incidence rate of DME in females (IRR 0.57; 95% CI 0.52–0.62) compared to males. Exposure to hormone replacement therapy estradiol (OR 0.42; 0.25–0.68), temazepam (0.23; 0.08–0.62) and allopurinol (0.61; 0.43–0.86) were associated with lower risk of DME, while use of insulin or insulin analogue (3.30; 2.99–3.64), sulfonylureas (1.21; 1.05–1.40), diuretic furosemide (1.90; 1.61–2.24), calcium channel blocker amlodipine (1.53; 1.34–1.75), ACE inhibitors ramipril (1.66; 1.46–1.89) and enalapril (1.38; 1.16–1.64) were associated with an increased risk of DME.ConclusionsLarge‐scale studies examining the incidence of DME are lacking. Our findings suggest that associations of systemic medications with the incidence of DME may shed light on the pathogenesis of complex DME, encouraging further studies.

show abstract

Section: Discussionmentioning

confidence: 99%